ArticleFrontiers in nutrition2025
Simple biomarkers based on CRP and albumin predict clinical outcomes in adult patients with T-cell acute lymphoblastic leukaemia.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Inflammation and malnutrition adversely impact outcomes in patients with various malignancies. Composite indices such as the C-reactive protein/albumin ratio (CAR), the CRP × fibrinogen/albumin ratio (CFA), and the modified Glasgow Prognostic Score (mGPS) integrate these parameters, although their prognostic role in T-cell acute lymphoblastic leukaemia (T-ALL) remains underexplored. Methods: In this single-centre retrospective study, 74 adults with T-ALL were included. CAR, CFA, and mGPS were calculated at diagnosis. Receiver operating characteristic curve analysis revealed the optimal cut-off values for the CAR (0.387) and CFA (0.396). Patients were stratified into low- and high-risk groups. Endpoints included rates of complete remission/complete remission with incomplete haematologic recovery (CR/CRi) at end-of-induction (EOI), minimal residual disease (MRD), overall survival (OS), and progression-free survival (PFS). Results: Patients with low CAR, low CFA, or mGPS0 achieved significantly higher rates of CR/CRi (all Conclusion: Pretreatment CAR, CFA, and mGPS are robust, accessible prognostic biomarkers in adults with T-ALL. Their integration into initial risk assessment could help guide personalized treatment strategies, including the identification of high-risk patients who may derive greater benefit from aggressive interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.